Cereno Scientific



Our vision is to develop innovative treatments to improve quality of life and prolong life for people with rare and common cardiovascular diseases.

April–June

Q2 report 2024

Contents

Financial calendar

Interim Report, Q3 2024..... 21 November 2024
End-Of-Year Report, Q4 2024.....25 February 2025
Annual Report 2024.....Week 20, 2025
Interim Report, Q1 2025.....22 May 2025
Annual General Meeting .....17 June, 2025

Cereno Scientific in brief

June 2023

Listed on Nasdaq First North Growth Market

(CRNO B)

(Spotlight Aktietorget 2016–2023)

Cereno Scientific is a pioneering biotech developing innovative, effective, and safe treatments for patients affected by rare and common cardiovascular diseases where great unmet medical needs persist.

Cardiovascular disease is the number one cause of death globally, killing nearly twice as many people as cancer. The term cardiovascular disease includes all diseases which involve the heart and/or the blood vessels. A majority of the complications associated with cardiovascular disease are caused by an occluding blood clot in a vein or artery which in turn, can lead to a heart attack, secondary heart failure, cardiac arrhythmias, stroke or other direct manifestations of blood clots in lungs or peripheral vessels.

Cereno's pipeline comprises:

- **Drug candidate CS1 in Phase II development** for the treatment of rare disease Pulmonary Arterial Hypertension (PAH).
- **Drug candidate CS014 in Phase I development** as a treatment for thrombosis prevention.
- **Drug candidate CS585 in preclinical phase under evaluation** as a treatment for cardiovascular disease.

Q2 summary

Financial overview

	Group		Parent company	
(SEK)	Apr–Jun 2024	Apr–Jun 2023	Apr–Jun 2024	Apr–Jun-2023
Result after financial items	-21 234 039	-10 686 053	-21 229 026	-10 679 871
Earnings per share before dilution	-0.08	-0.05	-0.08	-0.05
Earnings per share after dilution*	-0.01	-0.04	-0.91	-0.04
Equity/assets ratio	76.2%	95.4%	76.2%	95.4%
Cash and bank balances	85 596 493	85 291 722	85 472 485	85 219 725

	Group		Parent company	
(SEK)	Jan–Jun 2024	Jan–Jun 2023	Jan–Jun 2024	Jan–Jun-2023
Result after financial items	-36 467 324	-15 095 641	-36 462 311	-15 167 838
Earnings per share before dilution	-0.13	-0.06	-0.13	-0.06
Earnings per share after dilution*	-0.12	-0.06	-0.12	-0.06
Equity/assets ratio	76.2%	95.4%	76.2%	95.4%
Cash and bank balances	85 596 493	85 291 722	85 472 485	85 219 725

Earnings per share: Profit/loss for the period divided by 281,701,842 shares as of 30 June, 2024 and 233,775,234 shares as of 30 June, 2023.

* Earnings per share after dilution: Earnings for the period divided by the number of outstanding shares and the number of shares that can be subscribed for with outstanding warrants as of the balance sheet date 06/30/2024 and 06/30/2023, respectively.

Significant events during the second quarter

- On April 6–8, Sten R. Sörensen, CEO, Dr. Rahul Agrawal, CMO and Head of R&D, Dr. Björn Dahlöf, CSO and Fredrik Frick, Head of Clinical Operations, attended ACC's 73rd Annual Scientific Session & Expo (ACC.24) in Atlanta, organized by the American College of Cardiology.
- On April 9, Cereno announced that a patent had been approved (Notice of Allowance) in Europe, in the first patent family for the preclinical Prostacyclin Receptor Agonist program, which includes drug candidate CS585.
- On April 10, the Company announced the submission of a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for a First-In-Human, Phase I trial of novel histone deacetylase inhibitor (HDACi) drug candidate CS014.
- On April 10–13, Dr. Rahul Agrawal, CMO and Head of R&D, and Dr. Björn Dahlöf, CSO, attended ISHLT 44th Annual meeting and Scientific sessions, organized by The International Society for Heart and Lung Transplantation, in Prague.
- On April 11, Cereno announced that the Canadian authorities issued a patent for the drug candidate CS1's second patent family on Tuesday April 9.
- On April 16, the Annual General Meeting for the Company was held in Gothenburg.
- On May 2, Cereno announced the new Nomination Committee ahead of the Annual General Meeting 2025.
- On May 23, Cereno Scientific published the Interim Report for Q1 2024.

- On May 23, Sten R. Sörensen, CEO, presented the Company at ABGSC Investor Days in Stockholm.
- On June 3, Cereno Scientific announced that the Company will join the PVRI Roundtable (Pulmonary and Vascular Research Institute).
- On June 3–6, Sten R. Sörensen, CEO attended BIO 2024 in San Diego and engaged in partnering activities.
- On June 10, Cereno announced the move to a new office space at GoCo Health Innovation City in Gothenburg during June 2024.
- On June 15, preclinical data for drug candidate CS585, showing high selectivity for the IP receptor, was presented by Dr. Michael Holinstat, Director of Translational Research, at the EHA 2024 Hybrid Congress, in Madrid.
- On June 18, Cereno Scientific announced a granted approval from the European Medicines Agency (EMA) to initiate the first-in-human Phase I trial with novel HDAC inhibitor CS014.
- On June 28, Cereno Scientific announced that the Company had decided to close patient recruitment to the Phase II trial of CS1 in Pulmonary Arterial Hypertension (PAH) per July 1, as the Study Clinical Steering Committee concluded that there was sufficient data for evaluating the next steps in development.
- On June 28, the Company announced the first subject dosed in the first-in-human Phase I trial of novel HDAC inhibitor CS014.

Significant events after the period

- On July 2, Cereno Scientific's Board of Directors and Executive Management entered into a voluntary lock-up agreement for their shares and/or other securities in the Company until topline results for the Phase II trial of the Company's lead asset CS1 in the rare disease Pulmonary Arterial Hypertension (PAH) is presented in Q3, 2024.
- On July 5, the Company announced a final milestone payment to Emeriti Bio for CS014, which Cereno acquired from Emeriti in 2019.
- On July 9, Cereno Scientific announced expanded patent protection for CS1's second and third patent families in New Zealand and the US, respectively.
- On July 10, Cereno Scientific reported acquired warrants by members of the Company's management within the framework of the incentive program resolved at the Annual General Meeting.
- On July 10, the Company announced an extended loan maturity date for a loan of up to 90 MSEK issued by Fenja Capital II A/S (formerly Formue Nord Fokus A/S), from May 14, 2025, until March 31, 2026.
- On August 16, Cereno Scientific reported expanded patent protection for CS1's third patent family in Brazil.

Letter from the CEO

Cereno is on a quest to develop innovative, effective, and safe treatments for patients affected by rare and common cardiovascular diseases and we are currently pursuing this vision with a portfolio of three innovative drug candidates. I am pleased to report that we during the second quarter of 2024 solidified our position as a groundbreaking and innovative biotech company, now with two drug candidates advancing in clinical development. Our novel histone deacetylase (HDAC) inhibitor CS014 has entered Phase I development in Thrombosis prevention, and the first subjects have already been successfully dosed. We are also approaching a significant milestone with our HDAC inhibitor CS1. The Phase II trial of CS1 for the treatment of the rare disease Pulmonary Arterial Hypertension (PAH) was closed for patient recruitment in July based on a recommendation from the Study Clinical Steering Committee, which concluded that sufficient data had been collected for evaluating the next steps in development. We anticipate sharing topline results in Q3, 2024.

The Phase II trial of CS1 for the treatment of the rare disease Pulmonary Arterial Hypertension (PAH) was closed for patient recruitment in July based on a recommendation from the Study Clinical Steering Committee, which concluded that sufficient data had been collected for evaluating the next steps in development. We anticipate sharing topline results in Q3, 2024.

- Sten R. Sörensen, CEO

CS1 – Phase II trial in PAH is proceeding to topline

PAH is a rare disease and a specific form of high blood pressure in the pulmonary circulation. PAH is a progressive disease that ultimately leads to heart failure and poor lung function. Patients with PAH have a severe prognosis, with inadequate treatment options, and more than 50 percent of patients die within 5 years with a reduced quality of life throughout the course of the disease. There is a very high unmet need for more effective, safe and disease modifying new therapies. Cereno is on a mission to untap the potential of epigenetic modulation through HDAC inhibition to improve quality of life and prolong life for these patients. Indeed, Cereno's lead drug candidate CS1, is an HDACi with epigenetic effects and is being developed as a treatment for PAH with the aim of offering patients an effective, safe and disease-modifying drug.

The Phase II trial of CS1 for the treatment of the rare disease PAH was closed for patient recruitment in July based on a recommendation from the Study Clinical Steering Committee, which concluded that sufficient data had been collected for evaluating the next steps in development. We anticipate sharing topline results in Q3, 2024.

Earlier this year we were very pleased to obtain approval for Expanded Access to CS1 from the FDA. The request for Expanded Access was submitted after Cereno was urged to do so by an investigator in the Phase II trial, seeking permission to continue to administer the investigational drug, CS1, to patients post the conclusion of the study treatment. The Expanded Access Program (EAP) enables long-term access to CS1 for patients who have completed the Phase II trial of CS1 in PAH. During the second quarter we have progressed numerous regulatory, contractual and logistical matters related to the EAP. Site-specific contracts and IRB approvals are being finalized and we are positive that we will have the first patient dosed shortly.

The development program for CS1 in PAH is further supported by the Orphan Drug Designation (ODD) granted

by the US FDA in March 2020. To further strengthen the orphan drug status for CS1, we are now pursuing Orphan Medicinal Product Designation (OMPD) in the EU and we are expecting an approval during the fall.

Further strengthening our commercial strategy, the patent protection for CS1 has been significantly expanded during Q2, with new patents issued in Canada and New Zealand (second family), as well as in the US (third family).

Novel HDACi CS014 has entered clinical Phase I

CS014 is a new chemical entity and represents a novel approach to antithrombotic treatment without an increased risk of bleeding as documented in preclinical trials.

At the end of June, Cereno Scientific received approval by EMA to initiate a first-in-human Phase I trial of novel HDACi CS014 in healthy volunteers, after dedicated hard work from our team to evaluate and document the preclinical safety and efficacy. Only a few days later, the first subject was dosed, and we are excited that the Phase I trial is now in an active phase. This is a significant milestone for the CS014 program, as well as for Cereno Scientific as a whole, as we now have two of our three drug candidates in clinical phase. This marks the beginning of the next phase in the Company's growth journey, as we now will be advancing two clinical-stage candidates for patients with rare and common cardiovascular diseases

Just after the end of the second quarter, we also announced that the final milestone payment for CS014 was paid to Emeriti Bio, from which the drug candidate was acquired in 2019. The payment of the last milestone was triggered by the PCT patent application for CS014 recently having entered into national phase in more than 20 countries globally. The agreement with Emeriti Bio signed in 2019 transferred all rights for CS014, and the related compound family, from Emeriti Bio to Cereno. This final milestone payment concludes all remuneration under the agreement.

CS585, a promising antithrombotic treatment strategy

During the second quarter of 2024, Cereno secured further patent protection for the drug candidate CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular disease. The new patent expands the patent protection for the Prostacyclin Receptor Agonist program to also include Europe, one of the largest CVD markets, supporting a favorable commercial positioning in future treatments for cardiovascular disease.

During June, Dr. Michael Holinstat presented our new preclinical data for CS585 at the EHA (European Hematology Association) 2024 Hybrid Congress in Madrid, supporting the high selectivity of CS585. We are also very pleased that an abstract on CS585 has been accepted for presentation at the ESC (European Society of Cardiology) Congress in London on August 31. The ESC Congress 2024 is where the world's leading cardiology experts convene to transform patient care and advance the field through ground-breaking research, pioneering technologies, and collaborative initiatives. The congress serves as a catalyst for shaping the future of cardiovascular medicine on a global scale. We are delighted that CS585 is continuing to demonstrate the potential to ameliorate disease mechanisms relevant to cardiovascular diseases, in this case the highly prevalent condition thrombosis, and we look forward to continuing our work to progress CS585 into the clinic and to patients.

Cereno actively participating in medical and investor events, and pursuing external collaborations

Cereno has been active at several medical and investor events during the second quarter. We started the quarter by attending ACC.24 in Atlanta, hosted by the American College of Cardiology, raising awareness about our portfolio of innovative drug candidates, learning about the most recent advances and expanding our network among academic and industry actors. We also took the opportunity while in Atlanta, to meet with members of our Scientific Advisory Board as well as members of the Clinical Steering Committee for our Phase II trial of CS1. A few days later, Dr. Rahul Agrawal, CMO and Head of R&D, and Dr. Björn Dahlöf, CSO, attended The ISHLT 44th Annual meeting and Scientific sessions, organized by The International Society for Heart and Lung Transplantation, in Prague. At ISHLT, we learned more about the advances in the care of patients with advanced heart or lung disease, extended the Company's network within academia and industry and met with investigators to discuss the finalization of the Phase II study of CS1 in PAH and the Expanded Access Program for CS1. In May, I represented Cereno at BioEquity in San Sebastian, networking with fellow biotech leaders and investors looking to drive a paradigm shift in the treatment of rare and common CVD. I presented the Company's pipeline at ABGSC Investor Days in Stockholm in May and met with engaged shareholders and potential investors. I also participated at BIO International in San Diego in June, where I had many discussions with potential partners. In mid-June, Dr. Michael Holinstat attended EHA 2024 Hybrid Congress in Madrid, where he presented preclinical data for CS585.

In June, Cereno Scientific joined the PVRI Roundtable (Pulmonary and Vascular Research Institute), by exclusive invitation from the organization. We look forward to participating in PVRI's Innovative Drug Development Initiative (IDDI), addressing the most challenging issues faced by pharma, researchers, regulators, and clinicians and join a task force to stimulate awareness of new research in Pulmonary Hypertension.

During the period Cereno also initiated a collaboration with Rx Securities, to raise further awareness on the Company's portfolio of innovative drug candidates among institutional investors. This collaboration extends the analytical coverage in addition to the earlier initiated collaboration for analytical coverage by Edison.

Future outlook

The second quarter of 2024 has been transformational for Cereno, with CS014 entering into clinical development and the closing of patient recruitment to the Phase II trial of CS1 in PAH, now proceeding to topline results. We expect the coming months to be just as defining.

Looking ahead into the third quarter, we look forward to report topline results of the Phase II trial of CS1 in the rare disease

PAH, report on the progress of the EAP for CS1, pursuing the progress of the Phase I trial of CS014, continue engaging in high-level partnering activities and continue positioning Cereno Scientific to optimize the advancement of our pipeline within rare and common cardiovascular diseases.

To strengthen our financial position going into Q3 we, shortly after end of Q2, announced that we drew down the second payment of 45 MSEK of the loan issued by Fenja Capital II A/S (Formerly Formue Nord Fokus A/S) and simultaneously extended the maturity date of the loan of 90 MSEK from May 2025 to March 2026.

As this Q2 report reaches you, our team is preparing for optimal business impact at the ESC Congress 2024 in London, where I, together with our CMO and Head of R&D Dr. Rahul Agrawal and CSO Dr. Björn Dahlöf, will be meeting with leaders within the global cardiovascular community to continue raising awareness about our portfolio of innovative drug candidates, learn about the most recent advances in the cardiovascular field and expand our network among academic and industry actors. With important milestones having been reached and others soon to be reported, the interest in Cereno Scientific and our pipeline has increased considerably lately. We are eager to discuss our progress and future plans with current and potential future collaborators.

We continue to see a high level of engagement from interested and knowledgeable shareholders, which we very much appreciate. At Cereno we take great pride in our work, which we pursue through passion for our vision, high level competence and relentless grit. I am proud to say that our entire Cereno Team is fully dedicated to return your support by advancing our pipeline programs towards the milestones set for each of them.

Thank you for your continued support in our efforts to bring life-changing treatments to patients with great unmet need.

August 2024

Sten R. Sörensen
Chief Executive Officer
Cereno Scientific

Project portfolio

Cereno has a promising project portfolio of innovative drug candidates for rare and common cardiovascular diseases with major unmet medical needs. The Company's portfolio includes one Phase II program, one Phase I program and one preclinical program.

Clinical phase

Tolerability, safety and efficacy studies

CS1 – Phase II

The Drug candidate CS1, a new advanced reformulation of valproic acid (VPA), is an HDAC (histone deacetylase) inhibitor that works through epigenetic modulation with pressure-reducing, "reverse-remodeling", anti-fibrotic, anti-inflammatory and anti-thrombotic properties. CS1 is in Phase II development for the treatment of the rare disease Pulmonary Arterial Hypertension (PAH), with the aim of offering patients an effective, safe and disease-modifying drug.

CS014 – Phase I

The investigational drug candidate CS014, currently in Phase I development, belongs to Cereno's HDAC inhibitor program, capitalizing on the principle of epigenetic modulation. CS014 is a new chemical entity and represents a novel approach to antithrombotic treatment without an increased risk of bleeding as documented in preclinical trials.

Preclinical phase

Studies in the laboratory to fulfill requirements to start clinical studies.

CS585

The Drug candidate CS585 is an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular disease. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension.

Drug candidates in the portfolio



Cereno Scientific, pioneering HDAC inhibition in CVD

HDAC inhibitors are epigenetic modulators (changing gene expression without actually changing the genetic code) which have been shown to have a wide spectrum of potentially disease-modifying effects in CVD.

Research has indicated that HDACi can mitigate elevated blood pressure, inflammation, fibrosis, and reverse vascular changes, changes as well as prevent Thrombosis without increased risk of bleeding, all of which are hallmark features of widespread and severe cardiovascular diseases.

Clinical Phase II drug candidate CS1

Drug candidate CS1, is an HDAC inhibitor that works through epigenetic modulation, being developed as a treatment for the rare disease Pulmonary Arterial Hypertension (PAH). CS1 has the potential to be an effective, safe and disease-modifying drug. The aim of CS1's development is to offer improved quality of life and prolonged life for patients with PAH. A Phase II trial in the USA is ongoing in collaboration with the global healthcare company Abbott. Patient recruitment to the Phase II trial was closed per July 1st, 2024. Topline results will be shared in Q3, 2024.

CS1's unique efficacy profile addresses the underlying pathophysiology of PAH.
CS1 is an innovative formulation of Valproic Acid (VPA) that has received orphan drug status in the US for the treatment of PAH. CS1's active substance VPA works through epigenetic modulation with a multifold efficacy profile being pressure-reducing, reverse-remodeling and having anti-fibrotic, anti-inflammatory, and anti-thrombotic properties.

CS1's multi-fold disease modifying characteristics:



CS1's unique efficacy profile addresses many of the pathogenetic mechanisms of the rare disease PAH. CS1 has the potential to be an effective, safe and disease-modifying drug. The aim of CS1's development is to offer improved quality of life and prolonged life for patients with PAH.

CS1's properties have been demonstrated through in-vitro models, animal models, human physiological data, independent epidemiological studies and a successfully completed Phase I trial. In preclinical and clinical studies investigating anti-thrombotic effects, CS1 showed an improvement of the endogenous fibrinolytic system by supporting local thrombolysis of impending occlusive thrombosis through the effect on local release of t-PA and reduction of the blood levels of PA-1. In the Phase I clinical trial, CS1 demonstrated good safety and tolerability, robust reduction of PAI-1 and no problems with bleeding.

Phase II trial in PAH

The Phase II clinical trial aims to evaluate CS1's safety and tolerability as well as investigate exploratory efficacy in patients with PAH. The primary objective of the trial is to evaluate the safety and tolerability of the drug candidate CS1. Other standard endpoints used in PAH trials for this patient group will also be evaluated in an exploratory fashion. A validated estimate of risk is also calculated besides various biomarkers, quality of life and aspects of cardiac function.

Current status CS1

Patient recruitment to the Phase II trial CS1-003 was closed on July 1st, 2024, based on a recommendation by the Study Clinical Steering Committee, which concluded that there is sufficient data for evaluating the next steps in development. Topline results will be shared in Q3, 2024.

Cereno Scientific has during the last few months reported positive findings from the ongoing trial suggesting a potential clinical benefit of drug candidate CS1 in patients with the severe rare disease PAH. Further details of the trial need to be awaited to confirm these findings.

> We are very happy that we have reached this point in the development of CS1 and are excited that we now are entering the next phase towards sharing topline results in Q3. The Phase II trial of CS1 intends to primarily evaluate CS1's safety and tolerability and also explore efficacy in patients with PAH. This data will provide crucial insights for planning the subsequent pivotal trial of CS1 in PAH.

- Dr. Rahul Agrawal, Chief Medical Officer (CMO) and Head of R&D

Remarkable Patient Case Study data

A patient case study performed on the first patient having completed the trial at a specific clinic showed remarkable efficacy data. After 12 weeks of treatment with CS1, the patient showed a 30% reduction in pulmonary arterial pressure and a 20% increase in cardiac output. The patient's overall functional status was changed from NYHA/WHO functional class II to I at the end of the treatment period, meaning that the patient had next to normal functional physical capacity with CS1 added to stable conventional therapy.

In addition to the data related to the effects of CS1 in the PAH patient, the case study indicates that using the CardioMEMS permits safe daily remote monitoring of pulmonary arterial (PA) pressure over time in patients with PAH, permitting assessment of medication effectiveness on an individual patient level.

A collaboration with the global healthcare company Abbott allows Cereno to use Abbotts pioneering implantable technology CardioMEMS HF System in the Phase II-trial with CS1 in PAH.

The technology is used to be able to monitor pulmonary arterial pressure and other cardiopulmonary function of patients in the trial on a daily basis. Continuous monitoring enables the use of a smaller patient population to evaluate key parameters, enhancing resource efficiency in conducting the trial – a key element in Cereno's pursuit of innovative clinical development methods.

CardioMEMS is a safe method already approved for monitoring in heart failure. With the Phase II trial, Abbott and Cereno also have the opportunity to test the system on a new disease indication. The trial has received recognition for its innovative study design.

Positive findings from the Data Quality Control Review

Cereno reported in October 2023 that a Data Quality Control Review (DQCR), of data obtained by the CardioMEMS HF System from the first 16 patients, was concluded with positive findings. The data quality of the CardioMEMS measurements was found satisfactory with adherence to study protocol and with timely data transfers from the patient's home to the clinic. Initial efficacy findings showed a clinically meaningful reduction of pulmonary arterial pressure in several patients of a similar or greater magnitude as in the Patient Case.

The DQCR findings are not based on data from all patients participating in the Phase II trial and some patients in this analysis had not completed the full trial period. The final results of the trial may differ from the findings in the DQCR and should not in any way be seen as a guarantee regarding the outcome and conclusions of the upcoming final Phase II trial results.

Expanded Access Program for CS1 in PAH

Since January 30th 2024, CS1 is approved by the FDA for Expanded Access, as an extension of the ongoing Phase II trial evaluating CS1 in PAH. The Expanded Access Program (EAP) will provide Cereno with the opportunity to, under a formal FDA-approved protocol, collect safety and efficacy data from long-term exposure to CS1 in patients with PAH. This initiative not only supports the treatment of PAH patients but also enables Cereno to gather additional CS1 usage documentation for regulatory discussions and Phase IIb/III pivotal trial design planning.

FDA definition of Expanded Access

Sometimes called “Compassionate Use”, Expanded Access is a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.

Orphan drug designation

The development program for CS1 in PAH is further supported by the Orphan Drug Designation (ODD) granted by the US FDA in March 2020. Through the granted ODD, the FDA indicate that they believe that CS1 has the potential to offer patients with PAH a significantly improved treatment.

The FDA grants national Orphan Drug Designation to encourage the development of drugs intended for the treatment of rare diseases in the US. Several incentives are associated with orphan drug status to facilitate drug development and they include, among other things, seven years of market exclusivity in the US from approval, assistance from the FDA in the design of further clinical studies, and tax credits for qualified study costs.

Novel HDACi CS014

The investigational drug candidate CS014 belongs to the HDAC inhibitor program capitalizing on the principle of epigenetic modulation. In March 2019, CS014 was acquired from Emeriti Bio and has since been developed in a collaboration between Cereno, Emeriti Bio and University of Michigan.

The innovative drug candidate CS014 represents a novel approach to antithrombotic treatment without an increased risk of bleeding. CS014 is a new chemical entity (NCE) with a multi-modal mechanism of action as an epigenetic modulator – regulating platelet activity, local fibrinolysis, and clot stability for the prevention of thrombosis without increased risk of bleeding, as documented in preclinical studies. Given the potential for the disease-modifying properties seen with HDAC inhibition, additional cardiovascular benefits of CS014 may be expected, including amelioration of inflammation, fibrosis, vascular changes and elevated blood pressure. HDAC inhibition as a therapy to avoid thrombosis could fundamentally change the thrombosis prevention landscape and meet a major unmet medical need.

Preclinical data suggests that CS014 is an effective HDAC inhibitor that inhibits platelet activity, fibrin accumulation and small and large vessel thrombosis in a dose-dependent manner, while maintaining hemostasis. Also, when combined with rivaroxaban, CS014 inhibited the formation of platelet and fibrin-rich thrombosis without adding to the bleeding risk.[1] These data show that CS014 has the potential to enrich the toolbox of anti-thrombotic therapies in both venous and arterial thrombosis. With clinical use of the HDAC inhibitor CS014 with its epigenetic modulation capacity, it might be possible to prevent thrombosis without an increased risk of bleeding, a much-desired unmet medical need. Additional preclinical and clinical studies will be conducted to determine the first indication where CS014 has the greatest potential as a treatment to prevent thrombosis.

Current status of CS014 development

In the second quarter of 2024, CS014 entered Phase I development, with a first-in-human trial to evaluate the safety and tolerability of CS014 in healthy volunteers, at Clinical Trial Consultants (CTC) in Uppsala.

Phase I trial of CS014

The Phase I trial CS014-001 is titled "A First-in-human, Open-label Trial to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CS014 in Healthy Volunteers After Single and Multiple Administration".

The trial is a Phase I, open-label, FIH trial designed to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending oral doses of CS014 in healthy volunteers. The trial will be conducted in two parts:

- A single ascending dose (SAD) part (Part I) will explore safety, tolerability and PK of single ascending oral doses of CS014.
- A multiple ascending dose (MAD) part (Part II) will explore safety, tolerability, PK, and PD following multiple ascending doses of CS014, dosed for seven days.

The Phase I trial of CS014 will include around 48 subjects and is planned to be concluded in the middle of 2025.

[1] Stanger L, Holinstat M, Lambert S, Yalavarthi P, Bergh N, Dahlof B. HDAC Inhibitor CS014 Attenuates Thrombosis Alone and in Combination with Rivaroxaban without Increased Risk of Bleeding. Poster presented at: 65th ASH Annual Meeting & Exposition; December 9, 2023; San Diego, USA. https://ash.confex.com/ash/2023/webprogram/Paper186602.html

Novel IP Receptor Agonist CS585

Drug candidate CS585 is a highly potent, oral and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular disease. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Pulmonary Hypertension and Thrombosis prevention without increased risk of bleeding.

Preclinical data suggest that CS585 provides a new option of activating the IP receptor to decrease platelet reactivity and could represent the first viable option for targeting the IP-receptor on platelets for inhibition of thrombosis with a reduced risk of bleeding. The preclinical results with CS585, including a head-to-head comparison of CS585 and the FDA-approved IP receptor agonists selexipag and iloprost, indicate a favorable profile for inhibiting platelet activation and clot formation. CS585 was shown to have a higher selectivity and more sustained efficacy than the currently available IP receptor agonists.[2] CS585 demonstrated a sustained duration of action in mice in the ability to inhibit platelet activation through several routes of administration including oral.

The growing body of evidence around drug candidate CS585 supports favorable tolerability and efficacy in preclinical studies. Recently, the drug candidate was published in the top-tier journal Blood[3] showing that CS585 is a highly potent and selective compound given both orally and intravenously and prevents thrombosis for up to 48 hours as observed in preclinical studies. Following the publication, a commentary article[4] and the Blood Podcast[5] highlighted that the new preclinical findings of CS585 could be a significant milestone to improve anti-thrombotic treatment strategies without increasing the risk of bleeding.

A license agreement for drug candidate CS585 with the University of Michigan provides Cereno exclusive rights to further development and commercialization of CS585.

Research collaboration with the University of Michigan

The University of Michigan, located in Ann Arbor, Michigan, USA, is a leading public research institution renowned for its successful collaborations with the pharmaceutical industry. Dr. Michael Holinstat, an esteemed pharmacologist with a PhD from the University of Illinois in Chicago, heads Cereno's preclinical work at the University. He also serves as a Professor in the Department of Pharmacology, the Department of Internal Medicine (Division of Cardiovascular Medicine), and the Department of Vascular Surgery at the University of Michigan, leading translational programs in drug development for hemostasis and thrombosis. Dr. Holinstat's extensive research spans thrombosis, pharmacology, and hematology, and he has established a cutting-edge laboratory for studying pharmacological effects on platelets and coagulation, both in vitro and in vivo.

[2] Stanger L, Yalavarthi P, Lambert S, Rickenberg A, Goerger K, Gilmore D, Dahlof B, Bergh N, Holinstat M. CS585 Demonstrates Favorable Selectivity and Sustained In Vivo Action in Preventing Platelet Activation and Thrombosis Compared to Existing IP Receptor Agonists. Poster presented at: 65th ASH Annual Meeting & Exposition; December 9, 2023; San Diego, USA. https://ash.confex.com/ash/2023/webprogram/Paper186300.html

[3] Stanger L, Yamaguchi A, Yalavarthi P, Lambert S, Gilmore D, Rickenberg A, Luke C, Kumar K, Obi AT, White A, Bergh N, Dahlöf B, Holinstat M. The oxylipin analog CS585 prevents platelet activation and thrombosis through activation of the prostacyclin receptor Blood (2023) 42(18):1556–1569. https://doi.org/10.1182/blood.2023020622.

[4] Rondina MT. Targeting prostacyclin: all gain with no pain? Blood (2023) 142(18):1506–1507. https://doi.org/10.1182/blood.2023022227.

[5] Blood Podcast. (2023, November 2) *Targeting prostacyclin to inhibit platelet activation; MRD-tailored myeloma maintenance; AREG and HSC function in DNA damage repair deficiency and aging.* (Audio podcast). Retrieved from https://ashpublications.org/blood/pages/blood_podcast_s6_ep18.

The Group's Performance, January–June 2024

Financial performance

During the first two quarters of 2024, the Company has mainly invested in the implementation of the Phase II clinical trial with CS1 in PAH, in preparing for and initiating the Phase I clinical trial of CS014, in the development of the patent portfolio and in preclinical studies of CS585.

In April, the T03 warrants was transferred to shares and generated cash of 76.6MSEK before issue costs. At the end of the second quarter, the group had a cash balance of SEK 85.6 million and an equity ratio of 76.2 percent.

Risk factors

A number of risk factors can have a negative impact on Cereno Scientific's operations. It is therefore of great importance to take into account relevant risks in addition to the Company's growth opportunities. These risks are described without mutual arrangement and without claims to be comprehensive in the Company's prospectus issued in connection with the latest rights issue in May 2023 and which can be read on the Company's website.

Company structure and shareholding

Cereno Scientific Group comprises parent company Cereno Scientific AB and its US subsidiary Cereno Scientific Inc. The US subsidiary was formed on 20 December 2019, and is wholly owned by Cereno Scientific AB.

Company share

Cereno Scientific's B shares were listed on Spotlight Stock Market on 22 June 2016. Since 1 July 2023, the share is traded on Nasdaq First North Growth Markets as "CRNO B" ISIN-code SE0008241558.

Certified Adviser

Certified Adviser is Carnegie Investment Bank AB, Regeringsgatan 56, 103 38 Stockholm, who are responsible for the Company's compliance to the regulations of Nasdaq First North Growth Market.

Share capital

Cereno Scientific's share capital was, as of the balance sheet date 30 June 2024, divided into 281,701,542 shares. The Company has two classes of shares, of which 722,248 are A shares. The A share gives ten (10) votes per share. Each B share gives one (1) vote per share. Each share carries an equal right to a share in the company's assets and results. The share's quota value (share capital divided by the number of shares) amounts to SEK 0.10.

Warrants of convertible loans

The financing agreement concluded with the European High Growth Opportunities Securitization Fund on 1 March 2019 and consisted of convertible loans and associated warrants. The Company no longer has any outstanding convertible loans. During December 2021 Cereno Scientific

repurchased 1,105,262 warrants. There are no warrants that remain outstanding after 31 March 2024.

Warrants of series 2019/2023 N01 and series 2019/2023 S01

The Extraordinary General Meeting on 28 August 2019 resolved to issue 650,000 warrants, of which 450,000 relate to key persons (series 2019/2023 N01) and 200,000 relate to operational Board Members (series 2019/2023 S01). After the completed share issue in May 2023, the restated number of Class B shares that the warrants give entitlement to is 907,071 with a subscription price of SEK 10.94. The warrants can be used for subscribing for Class B shares during the period 1 April–31 October 2023.

Warrants of series 2019/2023 SAB01

On 6 September 2019, the Board of Directors of Cereno Scientific resolved to issue 300,000 warrants to members of the Company's Scientific Advisory Board (series 2019/2023 SAB01). After the completed share issue in September 2022, the restated number of Class B shares that the warrants give entitlement to is 418,648 with a subscription price of SEK 10.94. The warrant can be used for subscribing for Class B shares during the period 1 April 2023–31 October 2023.

Long-term employee stock option program (qualified employee stock options) for employees

The Extraordinary General Meeting on 28 February 2022 resolved to implement a long-term incentive program for employees of the Company, through the issue of not more than 3,000,000 qualified employee stock options, which will be granted to the participants without consideration. Each stock option entitles the participant to acquire one new share of series B in the Company at an exercise price amounting to SEK 0.10, equivalent of the share's quota value. Allocation of stock options to the participants shall be made no later than 31 December 2022. The allocated stock options vest for 36 months and may only be utilized to acquire new shares if the participant still is an employee of the Company and all other requirements for qualified employee stock options under the Swedish Income Tax Act are fulfilled. The participant may utilize allocated and vested stock options from the end of the vesting period up to and during the entire tenth year calculated from the date of allocation. The Meeting also resolved to issue not more than 3,000,000 warrants to enable delivery of new shares to the participants of the program. A total of 2,444,442 warrants were allocated to employees up to December 31, 2022. Taking into account employees who have left their positions, the remaining allocated warrants amount to 1,666,665. After the completed share issue in May 2023, the restated number of Class B shares that the warrants give entitlement to is 1,754,719.

Long-term employee stock option program (qualified employee stock options) for board members

The Extraordinary General Meeting on 28 February 2022 resolved to implement a long-term incentive program for board members of the Company, through the issue of not more than 1,111,111 qualified employee stock options, which will be granted to the participants without consideration. Each stock option entitles the participant to acquire one new share of series B in the Company at an exercise price amounting to SEK 0.10, equivalent of the share's quota value. Allocation of stock options to the participants shall be made no later than 31 December 2022. The allocated stock options vest for 36 months and may only be utilized to acquire new shares if the participant still is a board member or otherwise remain engaged in the Company and all other requirements for qualified employee stock options under the Swedish Income Tax Act are fulfilled. The participant may utilize allocated and vested stock options from the end of the vesting period up to and during the entire tenth year calculated from the date of allocation. The Meeting also resolved to issue not more than 1,111,111 warrants to enable delivery of new shares to the participants of the program. Taking into account Board Members who have left their positions, the remaining allocated warrants amount to 444,444. After the completed share issue in May 2023, the restated number of Class B shares that the warrants give entitlement to is 467,925.

Implementation of a long-term incentive program (warrants)

The Extraordinary General Meeting on 28 February 2022 resolved to implement a long-term incentive program for certain key individuals in the Company that cannot be allocated qualified employee stock options, through the issue of not more than 3,333,333 warrants. After the completed share issue in May 2023, the restated number of Class B shares that the warrants give entitlement to is 3,509,440. Of these, 807,171 had been allocated as of 31 December 2023. The warrants shall be issued the Company and then be transferred to participants in the program at a price corresponding to the warrants' market price at the time of the transfer, calculated pursuant to the Black-Scholes model. Each warrant entitles to subscription for one new share of series B in the Company at a subscription price corresponding to 150 percent of the volume-weighted average share price during the fifteen-day period which immediately precedes allocation. Subscription for new shares by virtue of the warrants shall be made during a one-year period starting three years from allocation. It was further resolved that board members and deputies shall be entitled to participate in the program.

Warrants of series 2023/2026:1 and series 2023/2026:2

The Extraordinary General Meeting on September 14 2023 resolved to issue 13,000,000 warrants of series 2023/2026:1 to be transferred to employees at market price, calculated

pursuant to the Black-Scholes model. Each warrant entitles to subscription for one new share of series B in the Company at a subscription price of 2 SEK. The subscription time is set to November 16–November 30, 2026. The Extraordinary General Meeting resolved to issue 7,000,000 warrants to some Members of the Board. The warrants of series 2023/2026:2 are transferred to the Board Members at market price, calculated pursuant to the Black-Scholes model. Each warrant entitles to subscription for one new share of series B in the Company at a subscription price of 2 SEK. The subscription time is set to November 16–November 30, 2026. The subscription price shall not be lower than the share's quota value. The portion of the subscription price that exceeds the share's quota value shall be transferred to the unrestricted share premium reserve.

Warrants of series 2023/2026:3 and series 2023/2026:4

The Extraordinary General Meeting on November 7 2023, resolved to issue a maximum of 250,000 warrants of series 2023/2026:4 to be transferred to employees at market price, calculated pursuant to the Black-Scholes model. One (1) warrant of series 2023/2026:3 provides the right during the period from 30 November 2026 up to and including 14 December 2026 subscribe to one share at a subscription price amounting to 200 percent of the volume-weighted average price of the Company's share of series B on Nasdaq First North Growth Market during the period from and including 24 October 2023 until and including 6 November 2023, however, never lower than the shares' quota value. The Extraordinary General Meeting resolved to issue 1,000,000 warrants to a new Member of the Board. The warrants of series 2023/2026:4 are transferred to the Board Member at market price, calculated pursuant to the Black-Scholes model. One (1) warrant of series 2023/2026:3 provides the right during the period from 30 November 2026 up to and including 14 December 2026 subscribe to one share at a subscription price amounting to 200 percent of the volume-weighted average price of the Company's share of series B on Nasdaq First North Growth Market during the period from and including 24 October 2023 until and including 6 November 2023, however, never lower than the shares' quota value.

The Extraordinary General Meeting on December 12 2023 resolved, in accordance with the Board of Director's proposal, to adjust the terms and conditions for the warrants of series 2023/2026:1 and 2023/2026:4, respectively, and necessary adjustments of the agreements between the holders of the warrants and the Company related to the respective incentive program.

The Extraordinary General Meeting also resolved, in accordance with a shareholder groups' proposal, to adjust the terms and conditions for the warrants of series 2023/2026:2 and 2023/2026:3, respectively, and necessary adjustments of the agreements between the holders of the warrants and the Company related to the respective incentive program.

Warrants of series 2024/2027:1

The Annual General Meeting of the Company held on April 16, 2024, resolved on an issue of a maximum of 4,000,000 warrants of series 2024/2027:1 to the Company, to be transferred to employees within the framework of an incentive program. The warrants shall be transferred at market price, calculated pursuant to the Black-Scholes model. Each warrant entitles to subscription for one new share of series B in the Company during the period from 30 April 2027 to 14 May 2027.

The AGM also resolved in accordance with a shareholder group's proposal to issue 1,000,000 warrants of series 2024/2027:2 to a key person in the company.

Audit

The company's auditor has not audited the Interim Report.

Principles of preparation for the Interim Report

The accounts in this Interim Report have been prepared in accordance with the Annual Accounts Act and the Swedish Accounting Standards Board BFNAR 2012:1 Annual Report and Consolidated Accounts (K3).

Upcoming financial reports

Interim Report, Q3 2024 ..... 21 November 2024
End-Of-Year Report, Q4 2024 ..... 25 February 2025
Annual Report 2025..... Week 20, 2025
Interim Report, Q1 2025..... 22 May, 2025

Annual General Meeting

The Annual General Meeting is planned to be held on June 17, 2025, in Gothenburg. The location of the AGM will be announced at the latest in conjunction with the notice of the AGM.

Share capital development

Year	Event	Ratio value (SEK)	Difference shares	Change (SEK)	Total number shares	Total share capital (SEK)
2012	Rights issue	1	50 000	50 000	50 000	50 000
2012	Directed issue	1	10 605	10 605	60 605	60 605
2016	Stock dividend issue	1	1 200	1 200	61 805	61 805
2016	Share split 100:1	10		556 245	61 805	618 050
2016	Subdivision A-/B- shares	0.10	6 118 695		6 180 500	618 050
2016	Directed issue	0.10			6 180 500	
2016	Directed issue	0.10	1 420 000	1 420 000	7 600 500	760 050
2016	IPO	0.10	450 000	45 000	8 050 500	805 050
2016	Conversion	0.10	2 940 000	294 000	10 990 500	1 099 050
2018	Conversion	0.10	188 679	18 868	11 179 179	1 117 918
2018	Conversion	0.10	444 444	44 444	11 623 623	1 162 362
2018	Conversion	0.10	540 540	54 054	12 164 163	1 216 416
2018	Conversion	0.10	483 870	4 838 700	12 648 033	1 264 803
2018	Conversion	0.10	419 354	41 935	13 067 387	1 306 739
2018	Conversion	0.10	384 614	38 461	13 452 001	1 345 200
2018	Conversion	0.10	269 230	26 923	13 721 231	1 372 123
2018	Conversion	0.10	307 692	30 769	14 028 923	1 402 892
2018	Conversion	0.10	333 333	33 333	14 362 256	1 436 226
2018	Conversion	0.10	285 714	28 571	14 647 970	1 464 797
2019	Conversion	0.10	533 333	53 333	15 181 303	1 518 130
2019	Conversion	0.10	666 666	66 667	15 847 969	1 584 797
2019	Conversion	0.10	3 333 333	333 333	19 181 302	1 918 130
2019	Rights issue	0.10	19 181 302	1 918 130	38 362 604	3 836 260
2019	Overallotment issue	0.10	1 724 137	172 414	40 086 741	4 008 674
2019	Remuneration issue	0.10	132 571	13 257	40 219 312	4 021 931
2020	Directed issue	0.10	31 600 000	3 160 000	71 819 312	7 181 931
2021	Share issue TO1	0.10	33 442 470	3 344 247	105 261 782	10 526 178
2022	Share issue TO2	0.10	32 253 062	3 225 306	137 514 844	13 751 484
2023	Rights issue	0.10	96 260 390	9 626 039	233 775 234	23 377 523
2024	Nyemission TO3	0.10	47 926 608	4 792 661	281 701 842	28 170 184
At end of period		**0.10**	**96 260 390**		**233 775 234**	

Number of average shares*

	Apr–Jun 2024	Apr–Jun 2023	Jan–Dec 2023
Before dilution	281 701 842	185 645 039	185 645 039
After dilution	309 158 926	195 496 122	228 455 687

* Number of outstanding shares including shares that can be subscribed for with outstanding warrants as of the balance sheet date.

Share and owners

The largest shareholders by 28 Jun 2024.

Owners	Capital	Votes
Avanza Pension	20.37 %	19.91 %
Pareto Securities AS	5.61 %	5.48 %
Gevrie, Dory	1.58 %	1.54 %
Jern, Claes Sverker	0.64 %	1.35 %
Ejlegard, Andreas	1.37 %	1.34 %
Butt, Jan	1.35 %	1.32 %
Nordnet Pensionsförsäkring AB	1.08 %	1.05 %
Bergh, Olof Niklas	0.19 %	0.90 %
Lundberg, Mårten	0.79 %	0.77 %
Borgquist, Niklas	0.74 %	0.72 %
Total ten largest owners	**34.3 %**	**33.5 %**
Other shareholders	65.7 %	66.5 %
Total (7 461 shareholders)	**100 %**	**100 %**

Share ownership by the Executive Management and Board of Directors

Stocks and other securities, owned privately and/or through companies, by 28 Jun 2024.

Owners	A-shares	B-shares	Warrants
Sten R. Sörensen, CEO and Board Member	-	1,098,514	5,666,666
Dr. Rahul Agrawal, CMO and Head of R&D	-	-	2,000,000
Dr. Björn Dahlöf, CSO	123,920	1,439,076	2,833,333
Julia Fransson, Director of Business Development	-	-	200,000
Eva Jagenheim, CFO	-	275,000	1,000,000
Nicholas Oakes, Head of Preclinical Development	-	-	583,333
Joakim Söderström, Chairman of the Board	-	1,540,000	3,000,000
Dr. Gunnar Olsson, Board Member	-	-	600,000
Dr. Anders Svensson, Board Member	-	488,200	1,100,000
Jeppe Øvlesen, Board Member	-	55,000	1,000,000

Group – Income statement

(SEK)	1 Apr 2024 30 Jun 2024 3 months	1 Apr 2023 30 Jun 2023 3 months	1 Jan 2024 30 Jun 2024 6 months	1 Jan 2023 30 Jun 2023 6 months	1 Jan 2023 31 Dec 2023 12 months
Net sales	-	-			-
Capitalised work for own account	23 891 829	10 630 187	45 504 236	26 056 801	49 276 646
	23 891 829	**10 630 187**	**45 504 236**	**26 056 801**	**49 276 646**
Operating expenses					
Other external costs	-36 377 654	-17 243 032	-64 841 791	-33 834 470	-71 152 162
Personnel costs	-6 571 314	-3 889 641	-12 841 724	-6 981 922	-18 748 415
Depreciation of tangible fixed assets	-24 091	-3 577	-27 668	-7 154	-14 308
Other operating cost	-540 914	-170 896	-1 052 047	-320 532	-4 011 820
Operating loss	**-19 622 144**	**-10 676 959**	**-33 258 994**	**-15 087 277**	**-44 650 060**
Loss from financial items					
Interest income and similar income	304	115	2 284	850	1 840 942
Interest expenses and similar expenses	-1 612 199	-9 209	-3 210 614	-9 214	-5 297 093
Loss after financial items	**-21 234 039**	**-10 686 053**	**-36 467 324**	**-15 095 641**	**-48 106 210**
Loss before tax	**-21 234 039**	**-10 686 053**	**-36 467 324**	**-15 095 641**	**-48 106 210**
Income taxes	-	-	-	-	-
Loss for the period	**-21 234 039**	**-10 686 053**	**-36 467 324**	**-15 095 641**	**-48 106 210**

Group – Balance sheet

(SEK)	30 Jun 2024	30 Jun 2023	31 Dec 2023
ASSETS			
Fixed assets			
Intangible assets			
Capitalised expenditures for development activities	227 987 531	159 946 952	182 483 295
Patents, trademarks, licenses and similar rights	13 780 255	13 096 752	13 780 255
	241 767 786	**173 043 704**	**196 263 550**
Tangible assets			
Fixtures, tools and installations	904 761	21 469	14 315
	904 761	**21 469**	**14 315**
Financial assets			
Other long-term receivables	9 753	9 983	9 264
	9 753	**9 983**	**9 264**
Total fixed assets	**242 682 300**	**173 075 156**	**196 287 129**
Current assets			
Current receivables			
Other receivables	2 876 131	1 002 291	1 123 911
Prepaid expenses and accrued income	1 624 333	338 031	406 641
	4 500 464	**1 340 322**	**1 530 552**
Cash and bank balance	**85 596 493**	**85 291 722**	**87 168 535**
Total current assets	**90 096 957**	**86 632 044**	**88 699 087**
TOTAL ASSETS	**332 779 257**	**259 707 200**	**284 986 216**

Group – Balance sheet cont.

(SEK)	30 Jun 2024	30 Jun 2023	31 Dec 2023
EQUITY AND LIABILITIES			
Equity			
Share capital	28 170 184	23 377 523	23 377 523
Other contributed capital	236 445 986	297 413 530	297 413 530
Other capital including loss for the year	-11 129 386	-73 151 659	-104 366 617
Equity attributed to the Parent Company's shareholders	**253 486 784**	**247 639 394**	**216 424 436**
Total equity	**253 486 784**	**247 639 394**	**216 424 436**
Long-term liabilities			
Other liabilities to credit institutions	45 400 000	400 000	45 400 000
	45 400 000	**400 000**	**45 400 000**
Current liabilities			
Accounts payable	26 353 751	6 999 683	6 930 366
Tax liabilities	-	344 150	-
Bridge loan	-	-	-
Other liabilities	1 623 778	643 849	1 231 118
Accrued expenses and deferred income	5 914 944	3 680 124	15 000 296
	33 892 473	**11 667 806**	**23 161 780**
TOTAL EQUITY AND LIABILITIES	**332 779 257**	**259 707 200**	**284 986 216**

Group – Change in equity

1 Jan–31 Dec 2023	Share capital	Other contributed capital	Other capital including profit/ loss for the year
At start of period	13 751 484	245 725 032	-57 965 096
Qualified employee warrants	-	-	1 670 687
Exchange rate differences when translating foreign subsidiaries	-	-	34 002
New share issue	9 626 039	67 382 273	-
Issue expenses	-	-15 693 775	-
Loss for the period	-	-	-48 106 210
At the end of the period	**23 377 523**	**297 413 530**	**-104 366 617**

1 Jan–30 Jun 2023	Share capital	Other contributed capital	Other capital including profit/ loss for the year
At start of period	13 751 484	245 725 032	-57 965 096
Warrants issued	-	-	-
Exchange rate differences when translating foreign subsidiaries	-	-	-90 922
New share issue	9 626 039	67 382 273	-
Issue expenses	-	-15 693 775	-
Loss for the period	-	-	-15 095 641
At the end of the period	**23 377 523**	**297 413 530**	**-73 151 659**

1 Jan–30 Jun 2024	Share capital	Other contributed capital	Other capital including profit/ loss for the year
At start of period	23 377 523	297 413 530	-104 366 617
Exchange rate differences when translating foreign subsidiaries	-	-	26 790
New share issue	4 792 661	71 889 912	-
Issue expenses	-	-3 077 507	-
Loss for the period	-	-	-21 234 039
At the end of the period	**28 170 184**	**297 413 530**	**-125 573 866**

Group – Cash flow statement

(SEK)	1 Apr 2024 30 Jun 2024 3 months	1 Apr 2023 30 Jun 2023 3 months	1 Jan 2024 30 Jun 2024 6 months	1 Jan 2023 30 Jun 2023 6 months	1 Jan 2023 31 Dec 2023 12 months
OPERATING ACTIVITIES					
Loss after financial items	-21 234 039	-10 686 053	-36 467 324	-15 095 641	-48 106 210
Adjustments for items not included in the cash flow					
Depreciations	24 091	3 577	27 668	7 154	14 308
Translation differences	-26 790	-34 534	7 153	-91 002	34 002
Accrued expenses for borrowings	818 304	-	818 304	-	-
Accrued interest cost	-	-	-	-	777 040
Qualified employee warrants	-	-	-	-	1 670 687
Income taxes	-	-	-	-	-
	-20 418 434	**-10 717 010**	**-35 614 199**	**-15 179 489**	**-45 610 173**
Cash flow from operating activities before changes in working capital	**-20 418 434**	**-10 717 010**	**-35 614 199**	**-15 179 489**	**-45 610 173**
Cash flow from changes in working capital					
Increase (-)/Decrease (+) in operating receivables	-1 680 337	484 200	-2 888 743	242 218	52 288
Increase (+)/Decrease (-) in operating liabilities	9 721 540	218 036	9 748 184	-2 074 422	8 642 852
Cash flow from operating activities	**-12 377 231**	**-10 014 774**	**-28 754 757**	**-17 011 693**	**-36 915 033**
Investing activities					
Acquisition of intangible assets	-23 891 829	-10 630 186	-45 504 236	-26 056 801	-49 276 646
Acquisition of tangible assets	-918 114	-	-918 114	-	-
Cash flow from investing activities	**-24 809 943**	**-10 630 186**	**-46 422 350**	**-26 056 801**	**-49 276 646**
Financing activities					
New share issue	76 682 573	77 008 312	76 682 573	77 008 312	77 008 311
Issue expenses	-3 077 507	-15 693 775	-3 077 507	-15 693 775	-15 693 775
New loan	-	-	-	-	45 000 000
Cash flow from financing activities	**73 605 066**	**61 314 537**	**73 605 066**	**61 314 537**	**106 314 536**
Cash flow for the period	**36 417 891**	**40 669 577**	**-1 572 042**	**18 246 043**	**20 122 856**

Cash and cash equivalents at start of period	**49 178 602**	**44 622 145**	**87 168 535**	**67 045 679**	**67 045 679**
Cash and cash equivalents at end of period	**85 596 493**	**85 291 722**	**85 596 493**	**85 291 722**	**87 168 535**

Parent company – Income statement

(SEK)	1 Apr 2024 30 Jun 2024 3 months	1 Apr 2023 30 Jun 2023 3 months	1 Jan 2024 30 Jun 2024 6 months	1 Jan 2023 30 Jun 2023 6 months	1 Jan 2023 31 Dec 2023 12 months
Net sales	-	-	-	-	-
Capitalised work for own account	23 891 829	10 630 187	45 504 236	26 056 801	49 276 646
	23 891 829	**10 630 187**	**45 504 236**	**26 056 801**	**49 276 646**
Operating expenses					
Other external costs	-36 372 640	-17 254 850	-64 836 777	-33 906 670	-71 227 587
Personnel costs	-6 571 314	-3 889 641	-12 841 724	-6 981 922	-18 748 415
Depreciation of tangible fixed assets	-24 091	-3 577	-27 668	-7 154	-14 308
Other operating cost	-540 914	-170 896	-1 052 048	-320 529	-4 011 817
Operating loss	**-19 617 131**	**-10 688 777**	**-33 253 981**	**-15 159 474**	**-44 725 481**
Loss from financial items					
Interest income and similar income	304	115	2 284	850	1 840 942
Interest expenses and similar expenses	-1 612 199	-9 209	-3 210 614	-9 214	-5 297 093
Loss after financial items	**-21 229 026**	**-10 697 871**	**-36 462 311**	**-15 167 838**	**-48 181 632**
Loss before tax	**-21 229 026**	**-10 697 871**	**-36 462 311**	**-15 167 838**	**-48 181 632**
Loss for the period	**-21 229 026**	**-10 697 871**	**-36 462 311**	**-15 167 838**	**-48 181 632**

Parent company – Balance sheet

(SEK)	30 Jun 2024	30 Jun 2023	31 Dec 2023
ASSETS			
Fixed assets			
Intangible assets			
Capitalised expenditures for development activities	227 987 531	159 946 952	182 483 295
Patents, trademarks, licenses and similar rights	13 780 255	13 096 752	13 780 255
	241 767 786	**173 043 703**	**196 263 550**
Tangible assets			
Fixtures, tools and installations	904 761	21 469	14 315
	904 761	**21 469**	**14 315**
Financial assets			
Shares in group company	941	941	941
	941	**941**	**941**
Total fixed assets	**242 673 488**	**173 066 114**	**196 278 806**
Current assets			
Current receivables			
Receivables from group companies	100 958	68 403	107 154
Other receivables	2 870 511	1 002 291	1 023 629
Tax receivables	113 777	-	38 352
Prepaid expenses and accrued income	1 510 556	338 031	406 640
	4 595 802	**1 408 725**	**1 575 775**
Cash and bank balance	**85 472 485**	**85 219 725**	**87 102 526**
Total current assets	**90 068 287**	**86 628 450**	**88 678 301**
TOTAL ASSETS	**332 741 775**	**259 694 564**	**284 957 107**

Parent company – Balance sheet cont.

(SEK)	30 Jun 2024	30 Jun 2023	31 Dec 2023
EQUITY AND LIABILITIES			
Equity			
Restricted equity			
Restricted equity	28 170 184	23 377 523	23 377 523
Ongoing share issue	-	-	-
Fund for development expenses	236 445 986	167 721 904	190 941 749
	264 616 170	**191 099 427**	**214 319 273**
Unrestricted equity			
Share premium reserve	68 812 405	51 688 498	51 688 498
Retained earnings	-43 516 962	20 029 567	-1 519 591
Profit/loss for the period	-36 462 311	-15 167 838	-48 181 632
	-11 166 868	**56 550 227**	**1 987 274**
Total equity	**253 449 302**	**247 649 654**	**216 306 547**
Long-term liabilities			
Other long-term liabilities	45 400 000	400 000	45 400 000
	45 400 000	**400 000**	**45 400 000**
Current liabilities			
Accounts payable	26 353 751	6 976 787	6 930 366
Tax liabilities	-	344 150	-
Other liabilities	1 623 778	643 849	1 231 117
Accrued expenses and deferred income	5 914 944	3 680 124	15 089 077
	33 892 473	**11 644 910**	**23 250 560**
TOTAL EQUITY AND LIABILITIES	**332 741 775**	**259 694 564**	**284 957 107**

Parent company – Change in equity

1 Jan–30 Jun 2024	Share capital	Fund for development expenses	Share premium reserve	Retained earnings	Net loss for the period
At start of period	23 377 523	190 941 749	51 688 498	-1 519 591	-48 181 632
Disposal according to AGM resolution	-	-	-51 688 498	3 506 866	48 181 632
Warrant issued	-	-	-	-	-
New share issue	4 792 661	-	71 889 912	-	-
Issue expenses	-	-	-3 077 507	-	-
Redistribution in equity	-	45 504 236	-	-45 504 236	-
Loss for the period	-	-	-	-	-36 462 311
At the end of the period	**28 170 184**	**236 445 986**	**68 812 406**	**-43 516 962**	**-36 462 311**

1 Jan–30 Jun 2023	Share capital	Fund for development expenses	Share premium reserve	Retained earnings	Net loss for the period
At start of period	13 751 484	141 665 103	55 565 518	18 268 153	-27 747 301
Disposal according to AGM resolution	-	-	-55 565 518	27 818 216	27 747 301
Warrant issued	-	-	-	-	-
New share issue	9 626 039	-	67 382 273	-	-
Issue expenses	-	-	-15 693 775	-	-
Redistribution in equity	-	26 056 802	-	-26 056 802	-
Loss for the period	-	-	-	-	-15 167 838
At the end of the period	**23 377 523**	**167 721 904**	**51 688 498**	**20 029 567**	**-15 167 838**

1 Jan–31 Dec 2023	Share capital	Fund for development expenses	Share premium reserve	Retained earnings	Net loss for the period
At start of period	13 751 484	141 665 103	55 565 518	18 268 153	-27 747 301
Disposal according to AGM resolution	–	–	-55 565 518	27 818 216	27 747 301
Warrant issued				1 670 687	
New share issue	9 626 039	–	67 382 273	–	–
Issue expenses	–	–	-15 693 775	–	–
Redistribution in equity	–	49 276 646	–	-49 276 646	–
Loss for the period	–	–	–	–	-48 181 632
Loss for the period	**23 377 523**	**190 941 749**	**51 688 498**	**-1 519 591**	**-48 181 632**

Parent company – Cash flow statement

(SEK)	1 Apr 2024 30 Jun 2024 3 months	1 Apr 2023 30 Jun 2023 3 months	1 Jan 2024 30 Jun 2024 6 months	1 Jan 2023 30 Jun 2023 6 months	1 Jan 2023 31 Dec 2023 12 months
OPERATING ACTIVITIES					
Loss after financial items	-21 229 026	-10 697 871	-36 462 311	-15 167 838	-48 181 632
Adjustments for items not included in the cash flow					
Depreciations	24 091	3 577	27 668	7 154	14 308
Accrued interest cost	818 304	-	818 304	-	777 040
Qualified stock warrants	-	-	-	-	1 670 687
	-20 386 631	**-10 694 294**	**-35 616 339**	**-15 160 684**	**-45 719 597**
Cash flow from operating activities before changes in working capital	**-20 386 631**	**-10 694 294**	**-35 616 339**	**-15 160 684**	**-45 719 597**
Cash flow from changes in working capital					
Increase (-)/Decrease (+) in operating receivables	-1 720 337	475 527	-2 944 602	169 210	40 512
Increase (+)/Decrease (-) in operating liabilities	9 673 848	3 473 118	9 748 184	-2 059 040	8 731 217
Cash flow from operating activities	**-12 433 120**	**-6 745 649**	**-28 812 757**	**-17 050 514**	**-36 947 867**
Investing activities					
Acquisition of intangible assets	-23 891 829	-10 630 187	-45 504 236	-26 056 801	-49 276 646
Acquisition of tangible assets	-918 114	-	-918 114	-	-
Cash flow from investing activities	**-24 809 943**	**-10 630 187**	**-46 422 350**	**-26 056 801**	**-49 276 646**

Parent company – cont.

(SEK)	1 Apr 2024 30 Jun 2024 3 months	1 Apr 2023 30 Jun 2023 3 months	1 Jan 2024 30 Jun 2024 6 months	1 Jan 2023 30 Jun 2023 6 months	1 Jan 2023 31 Dec 2023 12 months
Financing activities					
New share issue	76 682 573	77 008 312	76 682 573	77 008 312	77 008 311
Issue expenses	-3 077 507	-15 693 775	-3 077 507	-15 693 775	-15 693 775
Proceeds from borrowings	-	-	-	-	45 000 000
Cash flow from financing activities	**73 605 066**	**61 314 537**	**73 605 066**	**61 314 537**	**106 314 536**
Cash flow for the period	**36 362 002**	**43 938 701**	**-1 630 041**	**18 207 222**	**20 090 022**
Cash and cash equivalents at start of period	**49 110 483**	**41 281 024**	**87 102 526**	**67 012 503**	**67 012 503**
Cash and cash equivalents at end of period	**85 472 485**	**85 219 725**	**85 472 485**	**85 219 725**	**87 102 526**

The Board and the CEO hereby certify that the interim report provides a fair overview of the parent company and the group's operations.

Gothenburg, August 29, 2024,

Joakim Söderström
Chair of the Board

Sten R. Sörensen
Chief Executive Officer and Board member

Gunnar Olsson
Board member

Jeppe Øvlesen
Board member

Anders Svensson
Board member

Cereno Scientific

Cereno Scientific develops innovative treatments for rare and common cardiovascular disease. The lead drug candidate, CS1, is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties. A Phase II trial is ongoing (patient recruitment closed on July 1st, 2024) to evaluate CS1's safety, tolerability, and efficacy in patients with the rare disease pulmonary arterial hypertension (PAH). A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the trial. Two initiatives performed during the ongoing Phase II trial have shown positive findings suggesting the potential clinical benefit of CS1 in PAH patients. These initial findings are, however, not a guarantee of the final trial results that are expected in Q3 2024. Since January 2024, we are delighted that the FDA´s Expanded Access Program will enable patients with PAH, a serious life-threatening disease condition, to gain access to CS1 where no comparable alternative therapy options are available. Cereno's pipeline comprises two additional programs in development through research collaborations with the University of Michigan. Investigational drug CS014 is an HDAC inhibitor in Phase I development as a treatment for arterial and venous thrombosis prevention. The innovative drug candidate represents a groundbreaking approach to antithrombotic treatment. CS014 is a new chemical entity with a multi-fold mechanism of action as an epigenetic modulator – regulating platelet activity, fibrinolysis, and clot stability for the prevention of thrombosis without an increased risk of bleeding as documented in preclinical trials. On 28th of June, 2024, Cereno initiated a first-in-human Phase I trial of CS014. Preclinical candidate CS585 is an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular disease. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Pulmonary Hypertension and thrombosis prevention without increased risk of bleeding. CS585 was in-licensed from the University of Michigan in 2023. The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. Based in Kendall Square, Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). The Certified Advisor is Carnegie Investment Bank AB, CA@carnegie.se. More information is on www.cerenoscientific.com.

Cereno Scientific AB
Org.nr. 556890–4071
Visiting and Postal address: GoCo Health Innovation City
Förändringens gata 10
431 53 Mölndal, Sweden
Tel: +46 768 66 77 87